Objective and hypotheses: To compare the different efficacies between recombinant human GH (rhGH) alone and rhGH combined with low does stanozolol on improving growth of the girls with Turner syndrome (TS).
Method: TS girls were divided into two groups. Group 1 (15 cases) received rhGH therapy, aged (13.09±2.70) years, bone age (11.00±1.01) years, height was (131.46±8.22) cm. Group 2 (22 cases) received low does stanozolol combined with rhGH therapy, aged (13.37±2.09) years, bone age was (11.04±0.86) years, height was (129.21±8.19) cm. Treatment periods were one year. Growth velocity (GV), height S.D. score (HtSDS), ΔHtSDS, the change of bone age over the change of chronologic age (ΔBA/ΔCA) for both groups were measured or calculated.
Results: The GV was (6.33±1.44) cm/a and (8.13±1.87) cm/a for group 1 and 2 respectively, HtSDS change from (−3.44±1.02) to (−3.06±1.09) and (−4.21±1.19) to (−3.43±1.06), and ΔBA/ΔCA was (0.63±0.40) and (0.77±0.56) for group 1 and 2 respectively. The GV and change of HtSDS for group 2 were significantly better than group 1 (P<0.05). The GV was negative correlation with the age.
Conclusion: Comparing to the therapy with rhGH alone, combined therapy with rhGH and low dose stanazolol has advantage on improving GV without accelerating bone maturation among the girls with TS.
01 Oct 2015 - 03 Oct 2015